BioPharma Resources

Drug Trial Radar · NCT07153757

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

A Prospective, Randomized, Open-label, Non-inferiority, Phase III Study Evaluating the Efficacy and Safety of 2 to 3 Years of Adjuvant Endocrine De-escalation Therapy for ER-positive/HER2-negative Stage I Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 2,934 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,934

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Sep 1, 2033

Study completion Sep 1, 2033

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, randomized, open-label, non-inferiority Phase III clinical trial, planning to enroll 2,934 patients, with a 1:1 allocation to either the conventional endocrine therapy group or the de-escalation therapy group. The aim is to evaluate the safety and efficacy of 2-3 years of de-escalated endocrine therapy in patients with T1N0M0 potentially low-risk breast cancer, respectively.

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

  • Endocrine Therapy of Physician's ChoiceDrug

    This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-year disease-free survival in the per-protocol populationTime frame: 5 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 270 Dongan Road, Fudan University Shanghai Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.